ISPE Europe Annual Conference Announces Speaker Line-Up

Inaugural Event to Focus on Pharmaceutical Operations within the New Quality Culture

(PresseBox) ( Brussels, Belgium, )
Renowned pharmaceutical, regulatory and technology experts from around the world will speak at the very first ISPE Europe Annual Conference-Driving Effectiveness in Pharmaceutical Operations within the New Quality Culture scheduled for April 28 - 30 2014 in Frankfurt, Germany.

The programme will include an executive forum, keynote sessions and three different tracks to determine how operational challenges, quality system effectiveness and regulatory changes can merge with a new pharmaceutical paradigm.

The paramount speaker line-up includes over 60 top regulators; production, quality and development professionals. Prof.Dr Wolfram Carius, Senior Vice President, Biopharma; Joe DeFeo, President and CEO, Juran Institute, Inc.; John Pinion, Global Head of PT Quality and Compliance, Roche; Dr. Fergus Sweeney, Head of Inspections and Human Medicines Pharmacovigilance Division, European Medicines Agency; Dr. Martin Bergen, Managing Director, SecurPharm; Dr. Paul Rutten, Principal at McKinsey & Co; and Dr. Birgitte Holst, Director, Novo Nordisk/EFPIA, among many others, will deliver presentations addressing the industry's most pressing issues.

"This Annual Conference will provide a synoptic view to the challenges pharmaceutical operations are facing, from supply chain control, to the impact of new regulations on manufacturing and how to avoid drug shortages by installing a robust pharmaceutical quality system. Industry professionals will have the opportunity to discuss key issues with colleagues and with regulators from EFPIA, EMA, FDA along with national regulators of European countries" said the Executive Forum Chair Thomas Zimmer, Vice President, ISPE European Operations."

Speakers from companies such as Pfizer, Novartis, Juran Institute Inc., Sanofi - Aventis, Roche and others, will illustrate the new quality culture and clarify their visions for future operations. Sessions include topics such as the future of biopharmaceutical operations, the current drug shortages initiatives, the perceived trade-off between fulfilling GMP compliance and lean production, the implementation of the Falsified Medicines Directive and the future regulatory challenges.

For more information on this conference, including detailed agendas and registration information, visit:
Für die oben stehenden Pressemitteilungen, das angezeigte Event bzw. das Stellenangebot sowie für das angezeigte Bild- und Tonmaterial ist allein der jeweils angegebene Herausgeber (siehe Firmeninfo bei Klick auf Bild/Meldungstitel oder Firmeninfo rechte Spalte) verantwortlich. Dieser ist in der Regel auch Urheber der Pressetexte sowie der angehängten Bild-, Ton- und Informationsmaterialien.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an